Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

- Foong, Yi Chao, Merlo, Daniel, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria, Gresle, Melissa, Butzkueven, H, van der Walt, A, Zhu, C, MSBASE study group,, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan

Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis

- Brown, J. William L., Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessndra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francois, Terzi, Murat, Lechner-Scott, Jeannette

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

- Kister, Ilya, Spelman, Tim, Grand'Maison, Francois, Alroughani, Raed, Terzi, Murat, Boz, Cavit, Hupperts, Raymond, Lechner-Scott, Jeannette, Kappos, Ludwig, Pucci, Eugenio, Hodgkinson, Suzanne, Solaro, Claudio, Patti, Francesco, Butzkueven, Helmut, Duquette, Pierre, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

- Kister, Ilya, Spelman, Tim, Iuliano, Gerardo, Hupperts, Raymond, Pucci, Eugenio, Trojano, Maria, Butzkueven, Helmut, Alroughani, Raed, Lechner-Scott, Jeannette, Duquette, Pierre, Grand'Maison, Francois, Slee, Mark, Lugaresi, Alessandra, Barnett, Michael, Grammond, Pierre